AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a tiny zap save your sight? new trial for dry AMD
Disease control Recruiting nowThis study tests a device that delivers tiny electrical pulses through the eyelid to treat dry age-related macular degeneration (AMD), a leading cause of vision loss. About 100 people with intermediate to advanced dry AMD will receive either real or sham (inactive) treatments ove…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New pill for macular degeneration enters first human safety tests
Symptom relief Recruiting nowThis early-stage study tests the safety of an experimental oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The goal is to see if the drug is safe and how the body processes it. About 68 participants will take single or multiple d…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Symptom relief
Last updated May 26, 2026 11:28 UTC